Background: Refractory or relapsed Hodgkin's disease (HD) occurs in 10-50% of patients.
The treatment of choice for these patients is high-dose chemotherapy (HDCT) and …

Background: Despite multiple published studies reporting result of salvage regimens for
relapsed and refractory Hodgkin's lymphoma, there are no comparisons of different …

Background: Chemotherapy with Adriamycin, Bleomycin, Vinblastine, and Dacarbazine
(ABVD regimen) cannot cure all patients with Hodgkin lymphoma. In this study, we …

Despite the innumerable successes in curing patients with Hodgkin Lymphoma (HL) in the
front-line setting still up to 20% of patients will experience relapsed or refractory disease …

Background High-dose chemotherapy (HDT) followed by autologous stem-cell
transplantation (ASCT) is considered the gold standard in the treatment of patients with …

The management of relapsed or refractory Hodgkin's lymphoma (RR-HL) remains a
challenge for hematologists and oncologists. Salvage chemotherapy followed by autologous …

Within the past decade, newer salvage combination chemotherapy regimens have been
studied for relapsed or refractory HL, and have been shown to induce significant responses …

Abstract Background and Objectives Response to pre-transplant salvage chemotherapy
remains the most important prognostic factor for outcome in refractory or relapsed Hodgkin's …

Relapsed or refractory classical Hodgkin lymphoma (HL) remains a therapeutic challenge.
Patients with relapsed HL should be identified according to their prognostic factors at …

Hodgkin lymphoma is a highly curable malignancy, with an excellent prognosis. However,
around 10% to 25% of patients will have primary refractory or relapsed disease, despite …